Clinical trial · Interventional
Pore Excision, Curettage, and Injection of Cymetra for Pilonidal Disease
Pore Excision, Curettage, and Injection of a Tissue Scaffold as Treatment for Pilonidal Disease
NCT00493493CI-TRIAL-00000777unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Chronic pilonidal disease is a common problem with no ideal treatment. This is a prospective study that will evaluate the results of surgical pore excision, curettage, and injection of a regenerative tissue matrix, Cymetra, on patients with chronic pilonidal disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pilonidal Sinus | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| surgery (Pore Excision, Curettage, and Injection of Cymetra) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- wound failure, time lost from work or school, analgesic requirements, recurrence rates
- timeFrame
- 6 months
Secondary outcomes (1)
- measure
- infection rates, wound care requirements
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Any patient with pilonidal diseas
References
Publications (0)
Data not yet available
No reference posted for this study.